Chronic Low Back Pain
Radiofrequency ablation of the basivertebral nerve may lead to significant short-term reductions in pain and functional disability in patients with chronic low back pain.
Abuse-deterrent extended-release oxycodone (Xtampza® ER; Collegium Pharmaceutical) provided adequate pain relief for patients with chronic low back pain who were previously receiving immediate-release oxycodone.
Physiotherapy combined with routine or stabilization exercises is effective for reducing pain and improving muscle dimensions in patients with nonspecific chronic low back pain.
Gabapentinoid use presents significant risk for adverse events and provides few benefits for patients with chronic low back pain.
Early pain response to duloxetine predicts better outcomes in patients with chronic low back pain.
Radiofrequency denervation may be ineffective in alleviating chronic low back pain.
Radiofrequency denervation improved chronic low back pain arising from the facet joints.
Long-term, clinically important improvement in chronic low back pain can be achieved with lumbar total disc replacement and multidisciplinary rehabilitation in patients whose low back pain does not respond to conservative therapy.
Tanezumab is a NGF inhibitor and is a first-in-class agent to receive Fast Track approval.
A single glucocorticoid intradiscal injection provided relief from low back pain at 1, but not 12 months in patients with active discopathy.
Nektar Therapeutics announced positive results from the SUMMIT-07 Phase 3 study of NKTR-181 for the treatment of moderate-to-severe chronic pain.
Meta-analysis indicates short-term NSAID use is generally safe and can relieve pain, but lacks clinically important benefits.
For patients with chronic lumbar back pain, ablation of the basivertebral nerve improves self-reported outcome.
Lumbopelvic stabilization training provides therapeutic effects on chronic nonspecific low back pain conditions.
"Our study shows that clinically significant placebo effects can be produced even when patients are told that they are being given placebos."
Though these initial findings seem promising, the utility of the device may be limited to a small number of patients, according to Steven P. Cohen, MD.
Meta-analysis shows muscle relaxants are effective in reducing acute but not chronic low back pain.
Clinical Pain Advisor Articles
- Aetna-CVS Merger Approved
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?